1 Min Read
Oct 11 (Reuters) - Otsuka Holdings Co Ltd
* Otsuka and lundbeck announce initiation of two phase 3 trials of brexpiprazole in patients with Bipolar I disorder Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.